Cystatin C estimated glomerular filtration rate and all‐cause and cardiovascular disease mortality risk in the general population: AusDiab study
Nephrology2016Vol. 22(3), pp. 243–250
Citations Over Time
Elizabeth LM Barr, Anne T. Reutens, Dianna J. Magliano, Rory Wolfe, Zhong X. Lu, Ken Sikaris, Stephanie K. Tanamas, Robert C. Atkins, Steven J. Chadban, Jonathan E. Shaw, Kevan R. Polkinghorne
Abstract
In our community-based cohort, reduced eGFRcysC was associated with all-cause and CVD mortality. The addition of chronic kidney disease measures to risk prediction models improved overall risk stratification among those at low risk as opposed to those at high baseline risk of mortality.
Related Papers
- → Cystatin C, Renal Function and Cardiovascular Risk(2008)11 cited
- → Comparison of serum cystatin C and creatinine changes after cardiopulmonary bypass in patients with normal preoperative kidney function(2013)9 cited
- Correlation Analysis Between Glomerular Filtration Rate and Serum Cystatin C in Patients with Chronic Kidney Disease(2011)
- Comparison of cystatin C and creatinine in the detection of renal filtration function(2001)
- → Cystatin(2022)